The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 08, 2020
Filed:
Dec. 19, 2018
Applicant:
Reveragen Biopharma, Inc., Rockville, MD (US);
Inventors:
John M. McCall, Boca Grande, FL (US);
Eric Hoffman, Kensington, MD (US);
Kanneboyina Nagaraju, Columbia, MD (US);
Assignee:
ReveraGen BioPharma, Inc., Rockville, MD (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/573 (2006.01); A61K 31/57 (2006.01); C07J 5/00 (2006.01); A61K 31/575 (2006.01);
U.S. Cl.
CPC ...
A61K 31/573 (2013.01); A61K 31/57 (2013.01); A61K 31/575 (2013.01); C07J 5/0038 (2013.01); C07J 5/0053 (2013.01); C07J 5/0076 (2013.01); Y02A 50/479 (2018.01); Y10S 514/824 (2013.01); Y10S 514/825 (2013.01); Y10S 514/826 (2013.01); Y10S 514/903 (2013.01); Y10S 514/907 (2013.01);
Abstract
Provided herein is a pharmaceutical composition comprising a compound having the structural formula wherein the compound is present in an amount effective to treat or reduce the symptoms of muscular dystrophy. The therapeutically effective amount may be between 10 mg to 200 mg, or may be between 0.01 mg/kg to 10.0 mg/kg. Also provided are methods of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective of the above compound.